Expanded Indication for an Immune Checkpoint Inhibitor in Endometrial Cancer
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug...
Progress Against Cancer
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug...
The targeted therapy was approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone. The U.S....
The FDA approved the immunotherapy epcoritamab-bysp for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA)...
The FDA issued its first approval for the use of A KRAS G12C inhibitor in a tumor type other...
The FDA approved pembrolizumab, in combination with chemotherapy, for certain patients with endometrial cancer. The U.S. Food and Drug...
The FDA approved the bispecific T-cell engager blinatumomab for use in the consolidation phase of therapy for certain patients...
The immunotherapy durvalumab may be used with chemotherapy to treat certain endometrial cancers. The U.S. Food and Drug Administration...
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. ...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration...